Yahoo Finance

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary ...

ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Yahoo Finance

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Nasdaq

KALA Bio's KPI-012 Fails Phase 2b CHASE Study; Shares Plunge Over 90% In Pre-Market

(RTTNews) - KALA Bio, Inc. (KALA) on Monday announced that its CHASE Phase 2b study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED) did not meet the primary endpoint of ...
Hosted on MSN

Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kala Pharmaceuticals ( (KALA)) has shared ...